Shire Unit Can't Escape Genzyme False Advertising Suit

Law360, New York (November 30, 2012, 2:29 PM EST) -- A Massachusetts federal judge on Thursday refused to end a Genzyme Corp. suit accusing a Shire PLC unit of misleading consumers by advertising its genetic disease drug VPRIV as superior to Genzyme’s Cerezyme, saying there were several disputed issues still to decide.

U.S. District Judge Richard G. Stearns denied Shire Human Genetic Therapies Inc.’s motion to dismiss the suit, ruling Genzyme had legitimately questioned whether Shire’s scientific research findings arising from a clinical trial — which are normally protected by the First Amendment — could also...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.